key: cord-0847103-hl2vvcnc
authors: Jia, Lijing; Wei, Zijian; Zhang, Heng; Wang, Jiaming; Jia, Ruiqi; Zhou, Manhong; Li, Xueyan; Zhang, Hankun; Chen, Xuedong; Yu, Zheyuan; Wang, Zhaohong; Li, Xiucheng; Li, Tingting; Liu, Xiangge; Liu, Pei; Chen, Wei; Li, Jing; He, Kunlun
title: An interpretable machine learning model based on a quick pre-screening system enables accurate deterioration risk prediction for COVID-19
date: 2021-11-30
journal: Sci Rep
DOI: 10.1038/s41598-021-02370-4
sha: f8f4554a45bd538eda85622c21ddaa444dd6f1de
doc_id: 847103
cord_uid: hl2vvcnc

A high-performing interpretable model is proposed to predict the risk of deterioration in coronavirus disease 2019 (COVID-19) patients. The model was developed using a cohort of 3028 patients diagnosed with COVID-19 and exhibiting common clinical symptoms that were internally verified (AUC 0.8517, 95% CI 0.8433, 0.8601). A total of 15 high risk factors for deterioration and their approximate warning ranges were identified. This included prothrombin time (PT), prothrombin activity, lactate dehydrogenase, international normalized ratio, heart rate, body-mass index (BMI), D-dimer, creatine kinase, hematocrit, urine specific gravity, magnesium, globulin, activated partial thromboplastin time, lymphocyte count (L%), and platelet count. Four of these indicators (PT, heart rate, BMI, HCT) and comorbidities were selected for a streamlined combination of indicators to produce faster results. The resulting model showed good predictive performance (AUC 0.7941 95% CI 0.7926, 0.8151). A website for quick pre-screening online was also developed as part of the study.

www.nature.com/scientificreports/ China (see Additional file 1). In this study, patients who were either mild or moderate were treated as mild cases. All other patients were considered severe. The primary goal of the study was predicting whether patients would deteriorate from mild to severe status. Thus, we used longitudinal data derivates from patients whose initial status was mild but subsequently deteriorated. Specifically, 1537 of the 3028 patients had at least one status marked as severe, and 1140 of the 1537 patients experienced deterioration (other patients only experienced a transition from severe to mild or remained severe). We analyzed the time series of these 1140 patients. For each patient and at each time point, if the status changed from mild to severe, the time series data up to this point was labeled as positive (the experimental group), otherwise, the data was labeled as negative (the control group).

Data collection and processing. Electronic medical records (EMR) were collected from all patients at Huoshenshan Hospital during admission, including epidemiological, demographic, clinical, laboratory, medical history, exposure history, comorbidities, symptoms, chest computed tomography (CT) scans, and any treatment measures (i.e., antiviral therapy, corticosteroid therapy, respiratory support, and kidney replacement therapy). All data were reviewed by a trained team of physicians. To more accurately identify the high-risk factors that cause mild patients to deteriorate into severe/critical patients, mild patients were divided into severe (the experimental group) and non-severe (the control group) categories based on whether they deteriorated into severe cases during hospitalization (see Fig. 10A ). However, disease progression was dynamic and 35.7% of patients in the severe group experienced more than one deterioration event during hospitalization (an average of 2.9 times per patient). Each of these transitions was considered a positive sample in the study, allowing the model to acquire more information between features. In contrast, patients in the control group were in a constant mild state, providing a sufficient source of negative samples We divided the experimental group and the control group based on the state of patients. Therefore, in 1140 patients that deteriorated from mild to severe, the periods of mild state provided a source of negative samples, which led to class imbalances as the number of negative samples was significantly higher than that of positive samples. As such, a random under-sampling technique was used to establish two classes of equal size 19, 20 .

Model input included three broad classes of variables (i.e., features) that are commonly available in EMR: (1) demographic variables (e.g., age and sex); (2) comorbidities; and (3) clinical and laboratory results.

The type of missing data was Missing Completely at Random (MCAR). The probability of an observation being missing depended on the frequency of recording. For instance, a patient may have declined a test, or a doctor may have forgotten to record test results. There was no hidden mechanism related to features and it did not depend on any characteristic of the patients.

Values that were far from the true recorded values were defined as missing values because we did not want to leak distant future information. Specifically, if a feature for a patient was not recorded frequently, the data between distant record points was missing data. Therefore, if a patient had no or only a few records for a feature (missing rate ≥ 50%), we deleted all values for this feature and all the values were missing. The process above was carried out at the patient level, which means each patient's series was treated this way.

Next, we handled the missing values at the feature level. First, we removed features with missing rate greater than 50%. Then, we applied random forest imputation to fill missing values, which results in a better performance (see Fig. 10B ) [21] [22] [23] [24] . Overall, this produced 82 features for inclusion in the model (see Additional file 2). Furthermore, tenfold cross validation was adopted to evaluate model performance. In this process, the dataset was randomly partitioned into 10 equal-sized subsamples, nine of which were used to train the model, which was then validated using the remaining subsamples (see Fig. 10C ). Accuracy, recall, precision, F 1 score, and area under the receiver operating characteristic (AUC) curve were used to assess model performance (see Additional file 3).

Machine learning algorithms. This study considered interpretability to be a core requirement for machine learning model selection 25, 26 . Extreme gradient boosting (XGBoost) and logistic regression (LR) algorithms were used to predict whether a patient with mild COVID-19 symptoms would develop into a severe case. XGBoost, proposed by Chen et al. 27 , has produced unprecedented results for a variety of machine learning problems 25, [28] [29] [30] [31] . XGBoost works by using the decision tree as a weak classifier for iteratively modifying the residuals of previous models 27 . In addition, the algorithm includes a regularization component to control the complexity of the tree, thereby avoiding overfitting and simplifying the model 27 . Logistic regression (LR), a conventional machinelearning algorithm, has been widely used for classification tasks in medicine [31] [32] [33] [34] [35] [36] [37] . Rather than fitting a straight line or hyperplane, a logistic function can be used to constrain the output of a linear equation to between 0 and 1.

Shapley additive explanations (SHAPs) were used to enhance the interpretability of the results 38 . The goal of SHAP is to explain the prediction of an instance x by calculating the contribution of each feature to the prediction 39 . Additionally, partial SHAP dependency plots were used to illustrate the effect of individual feature changes on the severity of COVID-19. The SHAP dependence plot represents the marginal effects that each feature has on the predicted outcome of a machine-learning model and could reveal the exact form of this relationship (i.e., linear, monotonic, or more complex) 38 . An additional combined feature effect, after accounting for individual features like the interaction effect, was also considered in this study.

Ethical approval and consent to participate. The 

Patient characteristics. A total of 3028 patients were enrolled in the study, 1537 (50.8%) of whom deteriorated into severe cases (after excluding two patients with missing records). An analysis of these data revealed that 2071 mild to severe transitions occurred in 1537 patients (see Fig. 1 ). In this study, baseline characteristics for COVID-19 were acquired from the overall population (see Table 1 ) and individual samples (see Table 2 ). Among the entire cohort of 3,028 patients, a slight majority were male (51.1% male vs. 48.9% female). In addition, these patients generally suffered from symptoms such as fever, cough, fatigue, and dyspnea. Some patients exhibited neurological and gastrointestinal symptoms. However, compared with the patients in the non-severe group, those who deteriorated into severe cases tended to be older (median age of 63 vs. 57) and suffered from additional diseases such as hypertension ( vs. 0.1%) were administered to severe patients. Antibiotics were also used more commonly in severe cases, due to the presence of mixed bacterial or fungal infections in such cases (see Table 1 ). Laboratory indicators were also acquired from the sample data. The results for severe and non-severe patients differed significantly, particularly in the DD (0. Visualization of feature importance. An intuitive explanation of the importance of input model features (for clinicians) requires a ranking of features based on the XGBoost algorithm. The 15 selected features, correlating with severe COVID-19, were illustrated using a mean SHAP value plot (see Fig. 2 ). Among these, the top three features were PT (mean SHAP value of 0.5426), PTA (0.4450), and LDH (0.4140). In addition, a partial dependency plot was produced for each indicator, to illustrate the impact of individual metrics on the exacerbation of COVID-19. We found that lower PT, PTA, HCT, platelet count, and INR, as well as higher DD, L%, and APTT values were high-risk factors for severe COVID-19. Among the blood-based biochemical indica- www.nature.com/scientificreports/ tors, lower magnesium and globulin and higher LDH were correlated with disease deterioration. Additionally, we found that a higher BMI, a heart rate that was either too fast or too slow, and a high urine specific gravity were all risk factors for patient deterioration.

Comparisons between XGBoost and LR. The model used to predict malignant disease progression was constructed using LR and the XGBoost algorithm, respectively. XGBoost resulted in a significantly higher AUC than LR (mean AUC 0.8517, 95% CI 0.8433-0.8601 vs. AUC 0.6532, 95% CI 0.6421-0.6642, respectively; see Fig. 3 ). These results were used to identify optimal XGBoost parameters and rank the importance of individual features, to model the refinement metric. Detailed metrics describing the performance of these two models are provided in Table 3 . Taken together, these outcomes demonstrate the value of XGBoost and SHAP plots in providing physicians with an intuitive view of key features that can accurately predict whether malignant progression will occur in mild patients.

COVID-19 has been responsible for more total deaths than diseases with much higher overall case-fatality rates (e.g., SARS and MERS), due to increased transmission speed and a growing number of cases 2 . With the worldwide outbreak of COVID-19, SARS-CoV-2 infections have become a serious threat to public health. As such, early prediction and aggressive treatment of mild patients at high risk of malignant progression are critical for reducing Each sample in our dataset exhibited 82 features, including comorbidities, vital signs, coagulation, blood routine, blood biochemistry, and urine routine. The set of selected indicators must then be large enough to sufficiently represent a patient's state but not too large to be practical. This is because a patient's condition may deteriorate while awaiting the results of laboratory tests, which affects the timeliness of diagnosis and treatment. As such, a backward stepwise method was implemented in which all features were input to the XGBoost model and their corresponding Shapely values were calculated 41 . In each iteration, the feature with the smallest absolute Shapley value was removed from the model. This process continues to iterate until no features meet the criteria for elimination and the AUC of each iterative process is recorded (see Fig. 4 ). The one standard error rule was used to select 15 indicators with relatively high AUC values, thus balancing efficiency requirements while maintaining prediction performance 42 . In addition, SHAP plots were utilized to explain the overall effect of XGBoost in the form of specific feature contributions, which improved the interpretability of the model (Fig. 10D) .

Previous studies have focused on the use of diagnostic models for detecting COVID-19 infections, predicting mortality rates, or quantifying the risk of progression to a severe or critical state 43 . In addition, we quantified the importance of risk factors and illustrated how each factor affected the outcome. An approximate warning range was then acquired for each using partial SHAP dependency plots.

BMI, a commonly used international indicator to measure the degree of human obesity, has also attracted the attention of researchers in the study of risk factors for COVID-19 [44] [45] [46] [47] [48] [49] [50] . These results suggest that obese patients are more likely to progress to a severe state of COVID-19 44, 45 and BMI can be used as a clinical predictor of adverse consequences 46, 47, 49, 50 . Grigoris et al. suggested that COVID-19 patients with a BMI higher than 30 were at high risk of death 48 . The present study also found BMI to be an important risk factor affecting patient deterioration, with values in the 24-27 range representing high risk for both male and female, especially men with a BMI over 27 (Fig. 5A) .

Vital signs are the most accessible indicators for patients. As such, Dara et al. developed a tool for COVID-19 risk assessment using heart rate and respiratory rate 50 . Similarly, the present study identified increased or decreased heart rate as a risk factor, reflecting the degree of dyspnea in patients. The results suggested a heart rate of less than 70 or more than 100 BPM in COVID-19 patients should be considered an early warning sign (see Fig. 5B ).

Coagulation indicators have also been shown to play a vital role in predicting the deterioration of COVID-19 patients. PT, INR, DD, and APTT have been investigated in previous studies [12] [13] [14] [15] 48, [51] [52] [53] [54] [55] [56] . Similarly, we identified PT, PTA, INR, DD, and APTT as risk factors and further determined their approximate warning ranges. PT was found to be the single most important indicator of malignant progression, with levels below 13 s requiring increased attention (the normal range is 11-15 s). PT values above 13 s were negatively correlated with malignant progression (see Fig. 6A ). PTA was also identified as an important factor, with significant risk beginning below 96% (see Fig. 6B ). In addition, SHAP values were positive for INR < 1.08 (see Fig. 6C ). Previous studies have found that patients with COVID-19 are at higher risk for venous thromboembolism (VTE), which is associated with increased DD levels 53, 55, 56 . DD was identified as an important risk factor in this study, beginning above 0.5 mg/L (see Fig. 6D ). In contrast, lower levels (DD < 0.5 mg/L) were indicative of much lower risk, with far fewer participants progressing from mild to severe status. We also found that SHAP values were positive for APTT above 28, indicating increased risk (see Fig. 6E ). One of the primary contributions of this study is the first approximate early warning ranges for PT, PTA, INR, DD, and APTT levels. This could have important www.nature.com/scientificreports/ clinical significance for subsequent anticoagulant treatment timing and drug selection to prevent the malignant progression of COVID-19. Lymphocyte and platelet counts were also identified as biomarkers to predict patient deterioration 49, 54, 57 . Furthermore, L% levels above 30 and platelet counts above 280 10 9 /L were determined to be appropriate (see Fig. 7B ), while a platelet count below 100 was a risk factor (see Fig. 7C ). In addition, HCT values below 30 increased the risk of patient deterioration, while HCT above 40 was normal (see Fig. 7A ).

To further increase clinical efficiency, we propose using only 5 indicators to predict patient deterioration. By analyzing the weights of each indicator, and incorporating recommendations from clinicians, we selected PT, heart rate, BMI, and HCT. While each of these factors ranked highly and was easily accessible in clinical practice, PT ranked first in terms of importance. In addition, PT and HCT can be analyzed immediately using POCT (point of care testing), eliminating the need for complex laboratory procedures. BMI can be calculated by simply measuring the patient's height and weight. Heart rate can also be collected quickly using a portable device that monitors vital signs. Given the impact of comorbidities on COVID-19 deterioration in clinical practice, we added comorbidity to the model as a predictor for quick pre-screening. The XGBoost algorithm was used to make predictions with only these five indicators as input, producing excellent results (AUC 0.7941, 58 We also found LDH to be particularly useful as a risk www.nature.com/scientificreports/ factor at levels above 200 U/L (see Fig. 8A ). Bonetti et al. and Liang et al. found that CK was associated with poor COVID-19 outcomes 13, 16 . We also found CK to be a risk factor affecting patient deterioration (see Fig. 8B ) and magnesium levels below 0.93 mmol/L to be a key indicator of severe COVID-19. Conversely, appropriate magnesium levels, in the range of 0.9-0.93 mmol/L, appeared to protect patients from deteriorating further (see Fig. 8C ). Bonetti et al. and Albahri et al. found globulin to be a predictor of poor prognosis but did not determine corresponding early warning ranges 13, 59 . We found SHAP values to be positive for globulin levels below 25 g/L (a range of 25-28 is appropriate). Globulin levels that were either too high (> 28) or too low (< 25) had an adverse effect on the development of a patient's condition (see Fig. 8D ).

Although infectious SARS-CoV-2 has been successfully isolated from urine and feces of COVID-19 patients [60] [61] [62] , studies on the variations in urine routine indicators during the deterioration of COVID-19 patients have not yet been performed. As part of this study, we first found a urine specific gravity above 1.012 to be an early warning range (Fig. 9) .

This study developed a high-performing prediction model and offered valuable interpretations of quantitative findings. However, it does exhibit several inherent limitations that will need to be pursued further in a future study. For instance, the samples were analyzed retrospectively using EMR data that were not intended for the analyses performed. The Huoshenshan Hospital is a square-cabin hospital built to meet emergency needs 63 . Therefore, laboratory value indicators were not collected at regular intervals as frequently as those for critically ill patients, and data were collected at relatively long intervals. The amount of data for some of the laboratory indicators was less than that for patients in the ICU. And the impact of comorbidities on COVID-19 will be further. Although the proposed model performed well in the absence of data, the diagnosis of severe COVID-19 is a comprehensive process. As such, differences in patient profiles and healthcare could affect model performance in populations outside of China. In addition, this was a single-center study. The presence of data barriers between medical institutions in different regions prevents an external validation to verify the generalizability of the model. Finally, random under-sampling was employed to overcome the problem of class imbalances. This may have led to the discarding of potentially useful information, despite the high prediction accuracy.

An online tool for the prediction of COVID-19 patient deterioration. Based on these findings, we have developed an online tool to predict whether the condition of patients with COVID-19 will deteriorate. The trained model is embedded at http:// 180. 76. 234. 105: 8001. Clinicians can select two stepped index sets based on different scenarios. When higher accuracy is required for prediction, a set of 15 indicators can be selected. When timeliness is prioritized, a set of 5 indicators can be selected. The probability of deterioration is then output by the model. In addition, if a specific indicator is in the high-risk range, it will be highlighted (Fig. 10E) . This website provides a convenient and feasible means for early screening of severe patients, as well as a reference for clinicians in diagnosing patients and allocating healthcare resources.

A high-performance prediction model, based on the XGBoost (AUC 0.8517, 95% CI 0.8433, 0.8601) interpretable machine-learning algorithm, was developed using EMR data from 3,028 patients. A total of 15 high-risk factors and their approximate corresponding warning ranges were identified for predicting the malignant progression of COVID-19. In addition, this study proposed the first streamlined combination of indices to achieve good predictive performance with only two laboratory indicators (PT and HCT) and two simple combinations (heart rate and BMI: AUC 0.7941, 95% CI 0.7926, 0.8151). These combined stepped indices can meet the varying needs of clinicians, providing predictive accuracy and speed for practical clinical use. A website tool was also developed for online prediction, thus improving usability and applicability. In summary, these findings could reduce mortality, improve prognosis, and optimize the clinical treatment of COVID-19 patients. Figure 10 . Model development overview. (A) Data preparation and processing. Data were extracted from a database of patients diagnosed with COVID-19, including admission diagnosis, demographic information (e.g., age and sex), vital signs, and laboratory results. Patients were divided into severe (experimental group) and non-severe (control group) categories based on whether they deteriorated into severe cases. (B) Imputation based on Random Forest. Features with missing rates greater than 50% were removed. (C) Feature selection and tuning. (i) The dataset was divided into ten groups using tenfold cross validation, with nine of the groups serving as training data and one as test data. (ii) Gradient boosting tree training. (iii) Evaluation. The AUC, F1, precision, recall, accuracy and 95% CI values were recorded and used to evaluate the performance of each model for different features and parameters. (iv) The optimal model was selected using a 1 standard error rule.

(v) A comparison of results from XGBoost and logistic regression. (D) Interpretation. (i) The SHAP value was calculated for each feature. (ii) Partial dependence was plotted and analyzed with clinical experience. (E) The online prediction tool developed as part of the study (utilizing XGBoost). After selecting a combination of 15 or 4 indices, the model outputs the probability of mild/moderate COVID-19 patients deteriorating into the severe/ critical categories. Alerts can also be provided to clinicians when specific indicators enter an early warning range. www.nature.com/scientificreports/

The datasets generated and/or analyzed during the current study are not publicly available due the confidential policy of the National Health Commission of China, but are available from the corresponding author on reasonable request.

Received: 18 February 2021; Accepted: 8 November 2021

A novel coronavirus from patients with pneumonia in China

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention

COVID-19 and the anti-lessons of history

Full spectrum of COVID-19 severity still being depicted

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China

Clinically applicable AI system for accurate diagnosis, quantitative measurements, and prognosis of COVID-19 pneumonia using computed tomography

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A singlecentered, retrospective, observational study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study

SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients

Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy

A retrospective analysis of the coagulation dysfunction in COVID-19 patients

Early risk factors of the exacerbation of coronavirus disease 2019 pneumonia

Early triage of critically ill COVID-19 patients using deep learning

Machine learning based early warning system enables accurate mortality risk prediction for COVID-19

Machine learning to predict mortality and critical events in a cohort of patients with COVID-19 in New York City: Model development and validation

Interpretability and class imbalance in prediction models for pain volatility in manage my pain app users: Analysis using feature selection and majority voting methods

An interpretable machine learning model for accurate prediction of sepsis in the ICU

A: Handling complex missing data using random forest approach for an air quality monitoring dataset: A case study of Kuwait environmental data

MissForest-non-parametric missing value imputation for mixed-type data

Random forest missing data algorithms

Random forest-based imputation outperforms other methods for imputing LC-MS metabolomics data: A comparative study

An interpretable boosting model to predict side effects of analgesics for osteoarthritis

MediBoost: A patient stratification tool for interpretable decision making in the era of precision medicine

A scalable tree boosting system

From ranknet to lambdarank to lambdamart: An overview

Machine learning for predicting outcomes in trauma

Machine learning for the prediction of volume responsiveness in patients with oliguric acute kidney injury in critical care

Using a machine learning approach to predict mortality in critically ill influenza patients: A cross-sectional retrospective multicentre study in Taiwan

Logistic regression was as good as machine learning for predicting major chronic diseases

Comparison between logistic regression and machine learning algorithms on survival prediction of traumatic brain injuries

Developing prediction models for clinical use using logistic regression: An overview

Machine learning: An approach in identifying risk factors for coercion compared to binary logistic regression

Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes

Logistic regression was as good as machine learning for predicting major chronic diseases

Interpretable Machine Learning: A Guide for Making Black (Box Models Explainable

A unified approach to interpreting model predictions

Predicting COVID-19 malignant progression with AI techniques

Machine learning applications for the prediction of surgical site infection in neurological operations. Neurosurg

Sparsifying machine learning models identify stable subsets of predictive features for behavioral detection of autism

Prediction models for diagnosis and prognosis of covid-19 infection: Systematic review and critical appraisal

Obesity and COVID-19 severity in a designated hospital in Shenzhen

Obesity and COVID-19: An Italian snapshot

Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and metaanalysis

Obesity in patients with COVID-19: A systematic review and meta-analysis

Derivation and validation of a predictive score for disease worsening in patients with COVID-19

Early prediction of level-of-care requirements in patients with COVID-19

A Decision aide for the risk stratification of GU cancer patients at risk of SARS-CoV-2 infection, COVID-19 related hospitalization, intubation, and mortality

Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou

Simple nomogram based on initial laboratory data for predicting the probability of ICU transfer of COVID-19 patients: Multicenter retrospective study

Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: Prevalence, risk factors, and outcome

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis

Hematological findings and complications of COVID-19

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Risk factors for mortality in critically ill patients with COVID-19 in Huanggang, China: A single-center multivariate pattern analysis

Predictive accuracy of COVID-19 world health organization (WHO) severity classification and comparison with a Bayesian-method-based severity score (EPI-SCORE)

Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods

COVID-19 and its modes of transmission. SN Compr

Virological assessment of hospitalized patients with COVID-2019

Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient

Impact of hospital bed shortages on the containment of COVID-19 in Wuhan

I confirm that all methods were carried out in accordance with relevant guidelines and regulations. The methods were carried out in accordance with the TRIPOD (Transparent Reporting of studies on prediction models for Individual Prognosis Or Diagnosis) reporting guideline (issued in January 2015; www. tripod-state ment. org). The clinical classification standard is based on the diagnosis and treatment protocol for novel coronavirus pneumonia (6th edition), which is maintained by the National Health Commission of the People's Republic of China. It is confirmed that informed consent of all participants was obtained.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-02370-4.Correspondence and requests for materials should be addressed to W.C., J.L. or K.H.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.